In Vitro–In Vivo Correlation for Low-Clearance Compounds Using Hepatocyte Relay Method-Reference-Cited by-同舟云学术

In Vitro–In Vivo Correlation for Low-Clearance Compounds Using Hepatocyte Relay Method

Published:2013-07-15 Issue:12 Volume:41 Page:2018-2023
ISSN:0090-9556
Container-title:Drug Metabolism and Disposition
language:en
Short-container-title:Drug Metab Dispos

Author:

Di Li,Atkinson Karen,Orozco Christine C.,Funk Carrie,Zhang Hui,McDonald Thomas S.,Tan Beijing,Lin Jian,Chang Cheng,Obach R. Scott

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmaceutical Science,Pharmacology

Reference44 articles.

1. Metabolism of acebutolol-d6 in the rat correlates with the identification of a new metabolite in human urine;Andresen;Drug Metab Dispos,1979

2. Prediction of in vivo disposition from in vitro systems: clearance of phenytoin and tolbutamide using rat hepatic microsomal and hepatocyte data;Ashforth;J Pharmacol Exp Ther,1995

3. Effective Dosing Regimen of 1-Aminobenzotriazole for Inhibition of Antipyrine Clearance in Rats, Dogs, and Monkeys

4. Bayliss MK Cross DM (2000) The Hepatocyte Review, Springer, Dordrecht.

5. Effect of aging on the pharmcokinetics of atenolol, metoprolol and propranolol in the rat;Belpaire;J Pharmacol Exp Ther,1990

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Comparison of Machine Learning and Mechanistic In Vitro–In Vivo Extrapolation Models for the Prediction of Human Intrinsic Clearance;Molecular Pharmaceutics;2023-10-09

2. Recent advances in measurement of metabolic clearance, metabolite profile and reaction phenotyping of low clearance compounds;Expert Opinion on Drug Discovery;2023-08

3. HSF1 Pathway Inhibitor Clinical Candidate (CCT361814/NXP800) Developed from a Phenotypic Screen as a Potential Treatment for Refractory Ovarian Cancer and Other Malignancies;Journal of Medicinal Chemistry;2023-04-05

4. Large-scale perfused tissues via synthetic 3D soft microfluidics;Nature Communications;2023-01-12

5. Human pharmacokinetics prediction with an in vitro–in vivo correction factor approach and in vitro drug-drug interaction profile of bictegravir, a potent integrase-strand transfer inhibitor component in approved biktarvy^® for the treatment of HIV-1 infection;Xenobiotica;2022-12-02